DUBLIN – Versant Ventures raised $700 million across two new venture capital funds to continue its early stage investing in innovative biotechnology firms. In addition to its core $600 million fund, Versant Venture Capital VII, it has also raised a $100 million companion fund, Versant Voyageurs I, which will co-invest in Canadian firms the primary fund is also backing.